IDEAYA Biosciences (IDYA) Competitors $24.72 +0.19 (+0.77%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$24.72 0.00 (-0.02%) As of 09/16/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDYA vs. VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, LEGN, ABVX, RNA, and CYTKShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. IDEAYA Biosciences vs. Its Competitors Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics IDEAYA Biosciences (NASDAQ:IDYA) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Which has stronger valuation and earnings, IDYA or VRNA? Verona Pharma PLC American Depositary Share has higher revenue and earnings than IDEAYA Biosciences. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M309.49-$274.48M-$3.79-6.52Verona Pharma PLC American Depositary Share$42.28M216.64-$173.42M-$0.99-107.34 Do analysts prefer IDYA or VRNA? IDEAYA Biosciences presently has a consensus target price of $42.85, indicating a potential upside of 73.33%. Verona Pharma PLC American Depositary Share has a consensus target price of $109.00, indicating a potential upside of 2.57%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe IDEAYA Biosciences is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.81Verona Pharma PLC American Depositary Share 0 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Is IDYA or VRNA more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Verona Pharma PLC American Depositary Share's return on equity of -21.12% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -31.42% -29.45% Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% Which has more risk & volatility, IDYA or VRNA? IDEAYA Biosciences has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Do insiders & institutionals have more ownership in IDYA or VRNA? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. 2.5% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to IDYA or VRNA? In the previous week, IDEAYA Biosciences had 10 more articles in the media than Verona Pharma PLC American Depositary Share. MarketBeat recorded 21 mentions for IDEAYA Biosciences and 11 mentions for Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.52 beat IDEAYA Biosciences' score of 0.46 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 3 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Verona Pharma PLC American Depositary Share 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryIDEAYA Biosciences and Verona Pharma PLC American Depositary Share tied by winning 8 of the 16 factors compared between the two stocks. Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.15B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-6.5221.1675.8626.51Price / Sales309.49446.35528.72123.58Price / CashN/A45.4037.1760.46Price / Book2.029.6212.796.29Net Income-$274.48M-$53.28M$3.28B$270.51M7 Day Performance0.04%1.01%0.81%1.95%1 Month Performance1.60%4.58%4.60%6.33%1 Year Performance-30.91%8.35%70.39%25.62% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences3.9574 of 5 stars$24.72+0.8%$42.85+73.3%-32.9%$2.15B$7M-6.5280VRNAVerona Pharma PLC American Depositary Share2.2947 of 5 stars$106.300.0%$109.00+2.5%+252.4%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.813 of 5 stars$19.02+3.2%$17.33-8.9%+28.4%$9.16B$4.44B22.129,000Positive NewsROIVRoivant Sciences2.8008 of 5 stars$12.91-0.1%$16.38+26.8%+17.8%$8.82B$29.05M-18.44860RVMDRevolution Medicines4.2653 of 5 stars$41.06+1.4%$72.00+75.4%+0.4%$7.57B$11.58M-9.12250Positive NewsInsider TradeAnalyst RevisionGRFSGrifols3.8873 of 5 stars$10.11-0.2%$10.30+1.9%+6.4%$6.96B$7.81B8.6423,822Positive NewsRYTMRhythm Pharmaceuticals3.2982 of 5 stars$99.77-2.3%$101.57+1.8%+92.9%$6.78B$130.13M-33.15140Positive NewsLEGNLegend Biotech3.1915 of 5 stars$34.62-4.0%$74.22+114.4%-33.0%$6.66B$627.24M-39.342,609Positive NewsABVXAbivax2.7264 of 5 stars$90.00+2.2%$92.33+2.6%+616.7%$6.65BN/A0.0061Positive NewsShort Interest ↑RNAAvidity Biosciences2.0792 of 5 stars$48.05-4.6%$67.00+39.4%-0.7%$6.48B$10.73M-13.50190Analyst ForecastCYTKCytokinetics4.3654 of 5 stars$52.09-1.7%$75.38+44.7%-12.3%$6.34B$18.47M-10.21250Positive NewsInsider Trade Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Abivax Alternatives Avidity Biosciences Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDYA) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
